Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo; Drug
Lead sponsor: Othera Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more

Conditions: Hypertension (HTN), Pre Hypertension
Interventions: wall-squat, wall-squat-tradition; Behavioral
Lead sponsor: University of Hartford; Other
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: West Hartford, Connecticut

Conditions: Pulmonary Hypertension
Interventions: Treprostinil, Standard of Care; Drug · Other
Lead sponsor: Valley Health System; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Paramus, New Jersey

Conditions: Glaucoma
Interventions: Tube shunt surgery, Trabeculectomy, Mitomycin C; Procedure · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 85 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 12
States / cities: Sacramento, California • Gainesville, Florida • Miami, Florida + 9 more

Conditions: Pregnancy-Associated Hypertension, Gestational Hypertension, Preeclampsia, Eclampsia, HELLP Syndrome, Postpartum Hypertension, Stage 2 Hypertension
Interventions: Alabama Womb to Heart Solution (AW2H) Community Health Worker (CHW) Program, Usual postpartum care with self-measured blood pressure education and home blood pressure monitor; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 16 Years to 56 Years · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions: Allopurinol, Placebo, Chlorthalidone, Potassium chloride; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Critical Illness, Acute Kidney Injury, Sepsis, Septic Shock, Abdominal Compartment Syndrome
Interventions: Accuryn Monitoring System; Device
Lead sponsor: Potrero Medical; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension
Interventions: Water-only Fasting; Other
Lead sponsor: TrueNorth Health Foundation; Other
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Santa Rosa, California

Conditions: Cataract, Age-related Cataract, Circadian Rhythm Disorders, Glaucoma, Age Related Macular Degeneration
Interventions: Blue-light filtering intraocular lens, Conventional intraocular lens; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 10,192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Lisinopril; Drug
Lead sponsor: Uptal Patel; Other
Eligibility: 2 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more

Conditions: Hypertension, Blood Pressure, Cardiovascular Disease Other
Interventions: PAL2; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pulmonary Hypertension Secondary, Heart Failure
Interventions: Sodium Nitrite, Placebo Oral Capsule; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: metoprolol succinate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 30
States / cities: Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Seralutinib, Gereic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 33
States / cities: Fresno, California • Los Angeles, California • Sacramento, California + 26 more

Conditions: Dyslipidemia, Insulin Resistance Syndrome, Hypertension, Inflammation Chronic, Obesity & Overweight
Interventions: Step counts for predictable changes in body weight/compositon and cardiometabolic risk; Behavioral
Lead sponsor: Kennesaw State University; Other
Eligibility: 20 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kennesaw, Georgia

Conditions: Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions: H-1337 1.0%; Drug
Lead sponsor: D. Western Therapeutics Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions: Sitaxsentan, Sitaxsentan and Sildenafil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Obesity, Hypertension
Interventions: Atkins diet (low carbohydrate diet), DASH diet (high carbohydrate diet); Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild
Interventions: Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide; Diagnostic Test · Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Orange, California

Conditions: Altitude, Pulmonary Hypertension
Interventions: Bosentan administration; Drug
Lead sponsor: VA Loma Linda Health Care System; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost (SR); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 515 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 38
States / cities: Sun City, Arizona • Huntington Beach, California • Irvine, California + 32 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Naples, Florida • Bend, Oregon

Conditions: Glaucoma
Interventions: FDT visual field, Standard HVF; Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert; Drug · Device
Lead sponsor: ForSight Vision5, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Artesia, California • La Jolla, California • Newport Beach, California + 7 more

Search by objective public record fields.

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

The Effects of Brief Periods of Exercise on Blood Pressure

Early Intervention With Inhaled Treprostinil Among Patients With Exercise-Induced Pulmonary Hypertension (EPIH)

Primary Tube Versus Trabeculectomy Study

Community Health Worker Support to Lower Blood Pressure After a Pregnancy With High Blood Pressure

Uric Acid and Hypertension in African Americans

Collective Accuryn Physiologic Signals and Signatures

Water-only Fasting in the Treatment of Hypertension Patients

Association Between Light Spectrum and Survival After Cataract Surgery

Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant

Linkage, Empowerment, and Access to Prevent Hypertension

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)

Prescription of Step Counts for Targeted Changes in Body Composition and Cardiometabolic Risk in Overweight/Obese Adults

Open-Label Study of Safety of H1337 in Healthy Volunteers

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

Effectiveness of a Low Carbohydrate Diet Versus a High Carbohydrate Diet in Promoting Weight Loss and Improved Health

Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

Effect of Bosentan on Exercise Capacity at High Altitude

Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Frequency Doubling Technology (FDT) Mobile Visual Field Testing

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension